ANTIGENICS ANNOUNCES EXPANSION OF ITS LICENSE AND SUPPLY AGREEMENT WITH GLAXOSMITHKLINE BIOLOGICALS FOR QS-21 STIMULON
Antigenics Inc. announced that the company has signed expanded license and supply agreements for the use of QS-21 Stimulon adjuvant
with GlaxoSmithKline Biologicals, a vaccine division of GlaxoSmithKline (GSK). QS-21 is a key component included in several of GSK's proprietary adjuvant systems.
A number of GSK's vaccine candidates currently under development are formulated
with GSK's proprietary adjuvant systems containing QS-21.